These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults. Murray CH; Tare I; Perry CM; Malina M; Lee R; de Wit H Psychopharmacology (Berl); 2022 Jun; 239(6):1735-1747. PubMed ID: 34613430 [TBL] [Abstract][Full Text] [Related]
3. Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study. Hutten NRPW; Mason NL; Dolder PC; Theunissen EL; Holze F; Liechti ME; Feilding A; Ramaekers JG; Kuypers KPC Eur Neuropsychopharmacol; 2020 Dec; 41():81-91. PubMed ID: 33082016 [TBL] [Abstract][Full Text] [Related]
4. Modulation of long-term potentiation following microdoses of LSD captured by thalamo-cortical modelling in a randomised, controlled trial. Murphy RJ; Godfrey K; Shaw AD; Muthukumaraswamy S; Sumner RL BMC Neurosci; 2024 Feb; 25(1):7. PubMed ID: 38317077 [TBL] [Abstract][Full Text] [Related]
5. Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers. Bershad AK; Schepers ST; Bremmer MP; Lee R; de Wit H Biol Psychiatry; 2019 Nov; 86(10):792-800. PubMed ID: 31331617 [TBL] [Abstract][Full Text] [Related]
6. Role of the 5-HT Preller KH; Schilbach L; Pokorny T; Flemming J; Seifritz E; Vollenweider FX J Neurosci; 2018 Apr; 38(14):3603-3611. PubMed ID: 29555857 [TBL] [Abstract][Full Text] [Related]
7. Neural complexity is increased after low doses of LSD, but not moderate to high doses of oral THC or methamphetamine. Murray CH; Frohlich J; Haggarty CJ; Tare I; Lee R; de Wit H Neuropsychopharmacology; 2024 Jun; 49(7):1120-1128. PubMed ID: 38287172 [TBL] [Abstract][Full Text] [Related]
8. Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity. Glazer J; Murray CH; Nusslock R; Lee R; de Wit H Neuropsychopharmacology; 2023 Jan; 48(2):418-426. PubMed ID: 36284231 [TBL] [Abstract][Full Text] [Related]
9. Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study. de Wit H; Molla HM; Bershad A; Bremmer M; Lee R Addict Biol; 2022 Mar; 27(2):e13143. PubMed ID: 35106880 [TBL] [Abstract][Full Text] [Related]
10. LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder. Daldegan-Bueno D; Donegan CJ; Forsyth A; Sumner RL; Murphy RJ; Menkes DB; Evans W; Hoeh N; Sundram F; Reynolds LM; Ponton R; Cavadino A; Smith T; Roop P; Allen N; Abeysinghe B; Svirskis D; Bansal M; Muthukumaraswamy S Trials; 2024 Aug; 25(1):560. PubMed ID: 39182140 [TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Family N; Maillet EL; Williams LTJ; Krediet E; Carhart-Harris RL; Williams TM; Nichols CD; Goble DJ; Raz S Psychopharmacology (Berl); 2020 Mar; 237(3):841-853. PubMed ID: 31853557 [TBL] [Abstract][Full Text] [Related]
12. Microdosing Psychedelics: Current Evidence From Controlled Studies. Murphy RJ; Muthukumaraswamy S; de Wit H Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 May; 9(5):500-511. PubMed ID: 38280630 [TBL] [Abstract][Full Text] [Related]
13. Microdosing psychedelics: Motivations, subjective effects and harm reduction. Lea T; Amada N; Jungaberle H; Schecke H; Klein M Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967 [TBL] [Abstract][Full Text] [Related]